Study finds Daily Cognizin® Citicoline Oral Supplement Improves Attention in Adolescent Males

Daily Cognizin® citicoline supplementation also improved motor speed and decreased impulsivity in study participants

NEW YORK,  – Results of a double-blind, placebo-controlled, human clinical trial showed that nearly one month of oral supplementation with Cognizin® citicoline resulted in improved attention and motor function in healthy adolescent males.1

The study, published in the August edition of the Journal of Attention Disorders, followed seventy-five healthy male adolescents who received either a placebo, 250 mg of Cognizin® citicoline supplement or 500 mg of Cognizin® citicoline supplement for 28 days.1 After the 28-day study period, participants who received Cognizin® citicoline showed statistically significant increased motor speed, improved attention and decreased impulsivity compared to the placebo group.1

The authors noted the results of this study support previous research that has demonstrated citicoline’s positive impact on the brain’s frontal lobe, which is still maturing during adolescence.1 Further, enhanced motor speed, visual selective attention and reduced impulsivity could prove to be useful in an adolescent population experiencing neural development and increased risk-taking behavior.1

“We’re pleased with the findings that indicate daily supplementation with Cognizin® citicoline enhanced attentional processes in healthy adolescent males,” said lead researcher Dr. Deborah Yurgelun-Todd, Ph.D., University of Utah. “This is the first study of its kind that has examined the effects of Cognizin® citicoline in an adolescent population – natural supplementation is key, especially during adolescence, when the brain’s frontal lobe is still in development.”

“The exciting attention-supporting implications of this study are consistent with prior Cognizin® citicoline research conducted with healthy adult women, who also experienced improved attention after 28 days of daily Cognizin® citicoline oral supplementation,” said Danielle Citrolo, registered pharmacist and manager of technical services for Kyowa Hakko USA. “To see strong results, with minimal side effects, in an adolescent population opens the door for additional, ground-breaking research on brain health. We’re pleased to know that daily Cognizin® supplementation is a promising option for those seeking to positively impact attention and motor skills in healthy adolescents.”

Adolescent study participants completed the Ruff 2&7 Selective Attention Test, Finger Tap Test, and the Computerized Performance Test, Second Edition (CPT-II) at baseline and after 28 days of supplementation.1 In the study, side effects were monitored closely in the pediatric population. It was impressive to find that there were no significant differences in side effects between the treatment and placebo groups, consistent with previous studies that found few side effects associated with citicoline supplementation in adults.1

“Although we did not measure dopamine in this study, it is likely that citicoline may increase dopamine activity in healthy adolescent males and result in the changes observed in this study,” said Dr. Yurgelun-Todd. “Citicoline has been shown in previous studies to increase levels of dopamine, which may be one of the mechanisms through which citicoline improves motor and attentional functions.”

Though previous studies have examined improvement of deficits in motor and attentional abilities, this most recent study where participants took daily supplements of either 250 mg or 500 mg of Cognizin® citicoline, measured the enhancement of abilities in individuals with normative functions in the respective domains.1

For a brief, animated tutorial on how Cognizin® citicoline works in the brain, watch the following video:

https://www.youtube.com/watch?v=ckzXjbuIHPI

About COGNIZIN®
Cognizin is a branded form of Citicoline, a natural substance found in every cell of the body and especially vital to brain health.* Citicoline is broken down during intestinal absorption and, after passing through the blood/brain barrier, is reconstituted in the brain as citicoline.* Citicoline is a water-soluble compound that supplies precursors for the synthesis of phospholipids, including phosphatidylcholine, a major constituent of brain tissue*; helps maintain normal levels of acetylcholine, a chemical that regulates memory and cognitive function*; enhances communication between neurons*; supports visual function*; protects neural structures from free radical damage*; enhances metabolism and healthy brain activity*; and helps sustain healthy cellular mitochondria for sustained energy*. Cognizin is also highly stable, GRAS, ultra-pure and allergen-free. For more information on Cognizin, visit www.cognizin.com.

About KYOWA HAKKO USA, INC.:
KYOWA HAKKO USA, INC. is the North American sales office for KYOWA HAKKO BIO CO., LTD., an international health ingredients manufacturer and world leader in the development, manufacturing and marketing of pharmaceuticals, nutraceuticals and food products. Kyowa is the maker of branded ingredients including Cognizin® Citicoline, Pantesin® Pantethine, Setria® Glutathione, as well as Sustamine® L-Alanyl-L-Glutamine. For more information, visit www.kyowa-usa.com.

References

1. Yurgelun-Todd D et al. The Effect of Citicoline Supplementation on Motor Speed and Attention in Adolescent Males. Journal of Attention Disorders. 2015; 1557-1246.
* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Morning Sunshine Kitchen Introduces Probiotic Pro2Bites with GanedenBC30

The Nutritional Cookie Is Packed With Protein and the Digestive and Immune Support of GanedenBC30

CLEVELAND – OH – Pro2Bites are bite sized functional, probiotic cookies that contain whole grain prebiotics and a daily dose of GanedenBC30 for digestive and immune support. Pro2Bites cookies deliver probiotics to your body safely and deliciously! Pro2Bites are non-GMO and chock full of protein, fiber and omega 3’s and 6’s. Pro2Bites™ are fully functional cookies that offer the performance you crave in the indulgent cookie you deserve.

“We had been looking at Ganeden for a while and based on the growth of the probiotic market we identified an opportunity to work with Ganeden to include their amazing probiotic GanedenBC30 in our nutritional cookies,” said Lisa Harris, Founder of Morning Sunshine Kitchen. “We increased our product’s functionality and took a ‘bite’ out of the market. Ganeden made it very easy for us because GanedenBC30 seamlessly worked with our formula.”

Pro2Bites are now available for purchase online and in over 90 stores across the United States; and come in four delicious flavors:

Pro2Bites

  • Dark Chocolate Flax- Nutritious bites of oats, tart cranberries, almonds, sunflower seeds, dark chocolate chips & omega 3 rich golden flax seed.
  • Rise and Shine- Whole grain rolled oats, almonds, dark chocolate chips, cacao nibs, chia seed and infused with cold brewed coffee
  • 5 Spice Ginger Cashew- A warmly spiced whole grain cookie with crystallized ginger and cashews
  • Peanut Butter Berry- Nutritious bites of oats, dried cherries, white chocolate chips, peanuts and peanut butter sweetened with wildflower honey

 

About Ganeden
Ganeden is at the forefront of probiotic research and product development with an extensive library of published studies and more than 100 patents for probiotic technologies in the food, beverage, animal health, sports nutrition and personal care ingredients markets. Ganeden is best known for GanedenBC30®(Bacillus coagulans GBI-30, 6086), its patented, FDA GRAS, non-GMO, highly stable probiotic ingredient. Ganeden’s newest ingredient, Bonicel, is the first science-backed, probiotic-derived, personal care ingredient shown to dramatically reduce signs of aging. For more information about Ganeden and licensing opportunities visit GanedenProbiotics.com.

About Morning Sunshine Kitchen
Morning Sunshine Kitchen was founded in New York in 2010 by Lisa Harris. Originally a small company offering delicious, nutritional cookies, Lisa recognized an opportunity to expand their product line by adding probiotics to their cookie line. The result… Pro2Bites, a nutritional cookie with a full day’s dose of Probiotics. The new line provided value to Lisa’s customer base, an increase in functionality, and eased their expansion into national chain stores. Morning Sunshine Kitchen is now a trusted, global brand providing wholesome foods to mindful eaters. For more information, please visit MorningSunshineKitchen.com.

About GanedenBC30
Introducing GanedenBC30® (Bacillus coagulans GBI-30, 6086), Ganeden’s patented probiotic ingredient that can be found in more than 100 leading food, beverage, sports nutrition and companion animal products around the world. Unlike most other probiotic strains, GanedenBC30 is a spore-former which makes it highly stable and allows it to remain viable through most manufacturing processes, three years of shelf life and the low pH of stomach acid. The efficacy of GanedenBC30 is backed by over 20 published studies showing digestive and immune support and GanedenBC30 has an exceptional safety record with FDA GRAS status from the United States FDA. It can be formulated into virtually any food, beverage or companion animal product that is baked, boiled, frozen or squeezed…. including all hot or refrigerated beverages! For more information, please visit GanedenBC30.com.

Sustamine L-Alanyl-L-Glutamine During Strenuous Exercise May Ward Off Exhaustion Longer

Times to Fatigue Increased with Sustamine® Versus No Hydration*

New York City  – A University of Central Florida (UCF) study showed taking Sustamine® L-Alanyl-L-Glutamine during strenuous exercises may increase endurance and lengthen time to fatigue.1

The study, published June 22, 2015 in the Journal of American College of Nutrition, included 12 male endurance athletes who performed four endurance trials – each consisting of one-hour treadmill runs at 75% VO2 peak (milliliters of oxygen per body weight per minute moved or utilized) followed by a run to exhaustion at 90% VO2 peak. http://dx.doi.org/10.1080/07315724.2015.1009193

One trial allowed no hydration, with another consisted of consumption of a commercial sports drink (1L). The other two trials included low (600mg/L) and high (2g/L) doses of Sustamine® in the sports drink. Participants drank 250ml every 15 minutes. Plasma glutamine, glucose, electrolytes, and osmolality were measured prior to each run, and at 30-, 45-, and 60-minutes.

Sustamine® is a dipeptide of glutamine that provides several substantial benefits such as enhanced recovery, immune system support, and increased metabolic rate. On top of these benefits, research suggests that Sustamine® is absorbed more than 200 percent better than standard L-glutamine.2 This means you get better results while having to use less.

Time to exhaustion was significantly longer during the low- and high-dose Sustamine® trials compared to no hydration. There was no difference in time to exhaustion between sports drink only and no hydration. Plasma glutamine concentrations were significantly elevated at 45-minutes in the Sustamine trials, and remained elevated at 60 minutes during the high-dose test. Sodium concentrations increased from the beginning of exercise and remained stable for the duration of the one-hour run. At 60 minutes, plasma sodium was significantly lower in all trials compared with no hydration.

“Ingestion of Sustamine®

[the alanine-glutamine dipeptide] at either the low- or high-dose significantly improved time to exhaustion during high-intensity exercise compared to a no-hydration trial,” said Dr. Jay Hoffman, one of the study scientists and UCF Department of Sport and Exercise Science professor. “For endurance athletes such as long-distance runners, the addition of Sustamine® in hydration protocols may allow for longer times before exhaustion sets in.”

References
1) William P. McCormack PhD, Jay R. Hoffman PhD, Gabriel J. Pruna MS, Adam R. Jajtner MS, Jeremy R. Townsend MS, Jeffrey R. Stout PhD, Maren S. Fragala PhD & David H. Fukuda PhD (2015): Effects of l-Alanyl-l-Glutamine Ingestion on One-Hour Run Performance, Journal of the American College of Nutrition, DOI: 10.1080/07315724.2015.1009193
2) Harris RC, Hoffman JR, Allsopp A, Routledge NB (2012): L-glutamine absorption is enhanced after ingestion of L-alanylglutamine compared with the free amino acid or wheat protein. Nutr Res, 32(4): 272-7. DOI: 10.1016/j.nutres.2012.02.003.

About Sustamine
Sustamine® L-Alanyl-L-Glutamine is a stable dipeptide of L-Alanine and L-Glutamine. Sustamine is more easily absorbed by the body than complex protein molecules. This makes Sustamine a highly effective ingredient for hydration, endurance and recovery.* Vegetarian, allergen-free and the only GRAS L-Alanyl-L-Glutamine, Sustamine is also tasteless, odorless, and stable in liquids.
Sustamine is an ingredient that works on multiple levels to help rehydrate the body and sustain energy levels during exertion. Sustamine combines L-Glutamine (the most important amino acid for stimulating muscle protein synthesis) and L-Alanine (an amino acid needed for rebuilding your body’s glycogen stores). Sustamine enhances performance and recovery in three primary ways. It helps:

  • Replace lost electrolytes and fluids
  • Repair damaged muscle proteins
  • Refill the body’s energy stores

For more information on Sustamine, visit: www.sustamine.com.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

About Kyowa Hakko USA
Kyowa Hakko USA is the North American sales office for Kyowa Hakko Bio Co. Ltd., an international health ingredients manufacturer and world leader in the development, manufacturing and marketing of pharmaceuticals, nutraceuticals and food products. Kyowa is the maker of branded ingredients including Cognizin® Citicoline, Pantesin® Pantethine, Setria® Glutathione, as well as Sustamine® L-Alanyl-L-Glutamine. For more information visit http://www.kyowa-usa.com.

Sherry Torkos features NEM Eggshell Membrane on WJZY-TV Charlotte

Author and holistic pharmacist, Sherry Torkos speaks on “Exploring Natural Remedies” on WJZY-TV in Charlotte, NC. For those experiencing joint discomfort and issues with flexibility, Sherry recommends NEM® brand eggshell membrane as a trusted, high-quality ingredient to help maintain optimal joint health, and it is shown to work with just 500 mg daily within 7-10 days – much faster than most popular products for joint health. NEM Eggshell Membrane can also help support a healthy inflammatory response.*

Watch the video:

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Cognizin Citicoline Supplementation Effective At Reducing Cocaine Dependence in Bipolar Patients

New Study Results Offer Additional Combination Treatment Options for Patients

NEW YORK – The results of a randomized, double-blind, placebo-controlled clinical trial showed that Cognizin® citicoline (Jarrow® Formulas) was effective at reducing cocaine use, based on urine drug screens, in patients with bipolar disorder and cocaine dependence.1

The study, published in the American Journal of Psychiatry in Advance, included a total of 130 outpatients with bipolar I disorder and cocaine dependence, who received either Cognizin® citicoline or placebo add-on therapy for 12 weeks.1 Not only was citicoline well-tolerated for the duration of the study, but cocaine use was significantly reduced in the citicoline group.1 The positive treatment effects suggest that Cognizin® citicoline could be used as part of an augmentation strategy for the treatment of cocaine dependence in bipolar patients.1

Substance abuse has a well-documented, negative impact on bipolar disorder, but little research has been conducted on the treatment of patients with both bipolar disorder and substance dependence.1 Several studies report increased hospitalizations and other complications in patients with bipolar disorder who also have substance abuse disorders.1 The positive results of this study were similar to a previous pilot study of citicoline in patients with bipolar disorder and cocaine dependence, although notably, the studies used different designs.1

“The study results show that Cognizin® citicoline supplementation can offer additional support for patients undergoing treatment, particularly in the critical, early stages when Cognizin® supplementation proved most effective,” said E. Sherwood Brown, M.D., Ph.D., professor of psychiatry at the University of Texas Southwestern Medical Center and lead researcher of the study. “In addition, citicoline has a favorable safety profile and no known drug-drug interactions, which make it even more useful as a treatment option for dual-diagnosis patients.”

“Citicoline has several mechanisms of action, and based on results of previous studies, it’s possible that citicoline can impact dopamine levels in the brain,” said Danielle Citrolo, registered pharmacist and manager of technical services for Kyowa Hakko USA. “Previous research has shown that Cognizin® citicoline supplementation works in the brain to support focus and attention, increase the synthesis of brain cell membranes, and restore brain energy by 13 percent in associated study groups, meaning it has far-reaching potential for those who are looking to make a positive impact on their own brain health.”2,3

In this study, both the placebo and citicoline groups submitted to three weekly urine drug screens.1 Mood was assessed by the Inventory of Depressive Symptomatology-Self Report, the Hamilton Depression Rating Scale, and the Young Mania Rating Scale.1

This study’s authors noted that Cognizin® citicoline is the only treatment with positive findings in reducing cocaine use as assessed by urine drug screens in patients with bipolar disorder and cocaine dependence.1 Consistent with previous studies, the citicoline group in this study saw no significant group differences in manic or depressive symptoms following supplementation.1 At the same time, Cognizin® citicoline decreased cocaine use without impacting mood, meaning the efficacy of citicoline for reducing cocaine use not only holds promise as a treatment in this population, but could potentially hold true for other patients.1

About COGNIZIN®
Cognizin is a branded form of Citicoline, a natural substance found in every cell of the body and especially vital to brain health.* Citicoline is broken down during intestinal absorption and, after passing through the blood/brain barrier, is reconstituted in the brain as citicoline.* Citicoline is a water-soluble compound that supplies precursors for the synthesis of phospholipids, including phosphatidylcholine, a major constituent of brain tissue*; helps maintain normal levels of acetylcholine, a chemical that regulates memory and cognitive function*; enhances communication between neurons*; supports visual function*; protects neural structures from free radical damage*; enhances metabolism and healthy brain activity*; and helps sustain healthy cellular mitochondria for sustained energy*. Cognizin is also highly stable, GRAS, ultra-pure and allergen-free. For more information on Cognizin, visit http://www.cognizin.com.

About KYOWA HAKKO USA, INC.
KYOWA HAKKO USA, INC. is the North American sales office for KYOWA HAKKO BIO CO., LTD., an international health ingredients manufacturer and world leader in the development, manufacturing and marketing of pharmaceuticals, nutraceuticals and food products. Kyowa is the maker of branded ingredients including Cognizin® Citicoline, Pantesin® Pantethine, Setria® Glutathione, as well as Sustamine® L-Alanyl-L-Glutamine. For more information, visit www.kyowa-usa.com.

References
1. Brown ES et al. A Randomized, Double-Blind, Placebo-Controlled Trial of Citicoline for Cocaine Dependence in Bipolar I Disorder. Am J Psychiatry. 2015 May 22:appiajp201514070857.
[Epub ahead of print]
2. McGlade E. et al., Improved Attentional Performance Following Citicoline Administration in Healthy Adult Women Food and Nutrition Sciences. 2012;3:769-773.
3. Silveri MM et al. Citicoline enhances frontal lobe bioenergetics as measured by phosphorus magnetic resonance spectroscopy. NMR Biomed. 2008; 21(10):1066-75.
* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

TeaCrine Further Distances itself from Generic Competitors

CARLSBAD, CA — Increasingly aware of under-performing, generically-sourced theacrine products in the market, Compound Solutions, the exclusive global supplier of patent-pending TeaCrine®, today responded to manufacturers of the imitation products.

“While imitation may be the sincerest form of flattery, these sources are no imitations,” said Compound Solutions CEO, Matthew Titlow. “The generic supply doesn’t even come close to TeaCrine® quality, purity, regulatory compliance, intellectual property and scientifically substantiated claims.

In a market awash with potentially impure, generically sourced, ineffective ingredients, patent-pending TeaCrine® stands above the crowd.

” The response comes on the heels of the largest theacrine study ever performed in humans. The 60-subject, eight-week TeaCrine® clinical trial validated and added to previous human research proving the ingredient is safe and non-habituating. Giving consumers the same effect every time without risk of dependency is a critical differentiator that sets TeaCrine apart from its competitors.

Among additional key differentiators, the creators of TeaCrine® cite the following:

  • TeaCrine® is patent-pending in the USA and globally under the Patent Cooperation Treaty (PCT) with claims covering both biologically equivalent and naturally sourced theacrine.
  • TeaCrine® is the first and only ingredient with human clinical data. Additionally, TeaCrine was the subject of the first ever in-human research. The abstract of the first human study was published this year in the Journal of the International Society of Sports Nutrition (JISSN), and the second study is in process to be published. A third study utilizing TeaCrine® in humans to evaluate various functional efficacy outcomes has recently been completed with manuscript currently in preparation.
  • TeaCrine® is the only validated theacrine reference standard, and it has the only validated method to test for purity. In a market awash with potentially impure, generically sourced, ineffective ingredients, patent-pending TeaCrine stands above the crowd. 2
  • TeaCrine® is the only theacrine in the world with an abundance of safety and toxicity data (pre-clinical animal and human clinical), and the only one that is Informed-Choice and Informed-Sport certified. And among theacrine products, it stands alone as the only to be produced at an NSF-certified factory, fully compliant with current Good Manufacturing Practices.

“In the supplement industry, the line between borrowed science and validated science isn’t a fine one. We’re talking about big discrepancies here, and when health is on the line, we want to make sure we spell them out as clearly as we possibly can,” said Titlow.

But often, spotting the difference between TeaCrine®, which brings undeniable human clinical substantiation, safety data, marketable claims and compliance to the market and its generically sourced competitors is difficult when purchasing products. To make sure you’re getting pure teacrine, Compound Solutions recommends looking for the TeaCrine® logo on the product label.

“Patents and Lanham Act for unfair advertising and false advertising aren’t arbitrary,” said Titlow. “We’ve invested time, money, and a lot of science into creating a compliant product that works, and one that’s been substantiated by research from multiple groups. Generic brands not only have no right to claim this science, but those claims simply don’t apply to their inferior, copy-cat ingredients with potentially unknown health risks and concerns for tested athletes and discerning consumers. This is about safety and building a trusted product and brand that our customers can build theirs on.”

About Compound Solutions, Inc.
Compound Solutions, Inc. is the go-to company representing and distributing unique, patented nutraceutical ingredients for the sports nutrition, functional food and nutritional supplement markets. Compound Solutions is the exclusive global supplier of TeaCrine®

AstaReal Astaxanthin Shows Promise to Inhibit NAFLD-Hepatic Steatosis

Evidence from Administration to Werner Syndrome Patient

We here announce that our AstaReal® astaxanthin significantly improved NAFLD in patients with Werner syndrome, known as progeria, in a clinical study conducted by the Department of Clinical Cell Biology and Medicine, Graduate School of Medicine, Chiba University (Prof. Kotaro Yokote), which was published in the Journal of American Geriatrics Society (JAGS：June 2015, Vol. 63, No.6, 1271-1273).

What is Werner syndrome?
Werner syndrome, also called progeria, is a rare recessive disorder, clinically characterized by the juvenile onset of “symptoms generally regarded as an aging indicator.” In typical Werner syndrome patients, for example, symptoms specific to the elderly including white hair, hair loss and cataract start in their 20s with increasing risks of age-related diseases such as heart disease, type 2 diabetes, osteoporosis and arteriosclerosis. These diseases then develop one after another in young to middle age, resulting in an average life expectancy of around 50 years. According to genetic research, the cause is supposed to be unrepaired DNA accumulation due to an insufficiency of helicase, an enzyme contributing to DNA repair, or decreased particular tissue cells due to cell death accelerated by telomere shortening at an abnormally fast pace.

Result from the administration of a dietary supplement “AstaReal ACT”
A Werner syndrome patient who visited the Chiba University Hospital was suffering from diabetes mellitus. Liver computed tomography (CT) revealed many lipid droplets in liver cells, indicating Nonalcoholic Fatty Liver Disease (NAFLD) with serious hepatic steatosis.

After consultation with the patient, attending physicians including Dr. Minoru Takemoto and Prof. Yokote tried astaxanthin with an effect to extinguish active oxygen, by which the liver might be under oxidative stress due to active oxygen. For astaxanthin, the patient took 2 capsules of AstaReal ACT (containing natural astaxanthin of 6 mg per 1 capsule) everyday (i.e. astaxanthin at a dose of 12 mg/day). AstaReal ACT is supplied by the AstaReal Co., Ltd. of the Fuji Chemical group (President: Mitsunori Nishida) as a “dietary supplement” manufactured by extractive purification from Haematococcus pluvialis with biotechnology. After 3 months of treatment, liver CT showed a significant decrease of lipid droplets in the liver. The treatment with astaxanthin 12 mg/day was continued upon patient request for further 3 months, resulting in additional decrease of lipid droplets noted on liver CT. Blood test confirmed that the patients’ liver function returned to normal, with improvement in hepatitis markers including aspartate aminotransferase (AST) and alanine aminotransferase (ALT). Such preferable outcomes from the 6-month treatment encouraged the patient to continue to take astaxanthin for nearly 2 years after that without any recurrence of NAFLD nor side effects due to the long-term treatment.

Discussion
Werner syndrome patients tend to be insulin resistant due to visceral fat accumulation. In addition, their mitochondrial dysfunction leads to the high incidence of active oxygen, and enzymes to eliminate active oxygen are underactive. Since the liver easily receives longterm oxidative stress due to these factors, the patient in this case possibly experienced NAFLD.

Meanwhile, many basic studies have demonstrated that the strong antioxidant effect of astaxanthin stabilizes the plasma membrane, improves mitochondrial function, and inhibits DNA damage and inflammatory response as well. In a study with mouse models of diabetes mellitus, astaxanthin actually mitigated endoplasmic reticulum (ER) stress and inflammation in the liver. Such multiple effects probably brought the therapeutic success in this case.

Although the potential of astaxanthin treatment for nonalcoholic steatohepatitis (NASH) has already been expected from the result of a study with NASH mouse models conducted by Associate Prof. Tsuguhito Ota, et al, the Kanazawa University Brain/Liver Interface Medicine Research Center (a health column, the Sankei Shimbun, April 8 2014), this is the world’s first report of a clinical study involving human subjects. The result mentioned above was obtained from 1 patient with rare genetic disease, but it is a very valuable case report in that the patient had a clear etiopathogenesis and medical history. For further data on this clinical study, we will present at the 62nd Kanto/Koshinetsu regional meeting of the Japan Geriatrics Society held on September 26 of this year.

PubMed
http://www.ncbi.nlm.nih.gov/pubmed/26096415

About NAFLD
Excessive drinking and hepatitis virus infection have been attributed so far in causing hepatic cirrhosis and hepatitis. In order to prevent or treat these diseases, the limitation of alcohol use and virus eradication with antiviral agents are considered to be effective, and in fact, they have provided expected efficacy. However, NAFLD, a symptom causing hepatitis in the absence of excessive drinking history and virus infection, is often seen in recent days, which is becoming a major issue to overcome. NAFLD develops even in people with obesity, as well as metabolic syndrome, and may lead to hepatic steatosis. In Japan, there are many people with NAFLD, including 10 million carriers. In 10% to 20% of them (1 million to 2 million people), this condition progresses to NASH, resulting in hepatic cirrhosis and hepatitis. Diet modification to prevent NAFLD and the search for drugs or health foods to prevent/inhibit NASH are in urgent demand.

For more information please contact: global-contact@astareal.co.jp

Natreon Receives Strategic Investment from DSM

New Brunswick, NJ, USA –Natreon, Inc., a leading supplier of scientifically proven Ayurvedic ingredients for the dietary supplement, personal care and food and beverage markets , has received an equity investment from DSM Venturing B.V., the corporate venture capital arm of the global Life Sciences and Materials Sciences company, Royal DSM.

Natreon’s CEO & Chairman, Dr. Sanni Raju, commented that “We are pleased to welcome DSM as a strategic investor as we expand Natreon’s clinically proven, high quality Ayurvedic product lines. DSM is a global leader in the dietary supplement market and their expertise and domain knowledge will help accelerate our growth. ”

Greg McParland, Senior Investment Manager of DSM Venturing says: “Natreon’s focus on rigorous science and clinically demonstrated natural herbal supplements separates them from their peers. Their products are focused on highly relevant health and wellness categories that consumers are demanding. We are looking forward to supporting the Natreon team as they expand their business.”

About Natreon Inc.
Natreon, Inc., located in New Jersey with a state of the art R&D facility in Kolkata, India, is focused on developing and marketing clinically backed Ayurvedic products. Natreon’s current product portfolio includes Capros® for heart health, Sensoril® for stress and cognition, PrimaVie® for mitochondrial energy and collagen gene up regulation, Crominex® for blood glucose support and heart health, AyuFlex® for joint health and Ayuric™ for hyperuricemia. Several other products are in the R&D pipeline.

Capros®, Sensoril®, PrimaVie®, Crominex®, AyuFlex® and Ayuric™ are trademarks of Natreon, Inc.

About DSM – Bright Science – Brighter Living™
Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences, DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated companies deliver annual net sales of about €10 billion with approximately 25,000 employees. The company is listed on Euronext Amsterdam. More information can be found at www.dsm.com.

OmniActive Presents Poster on Study Featuring Lutemax 2020

Soluble Lutein Inhibits Cholinesterase and Reduces Ultraviolet Radiation-Induced Inflammation and Immunosuppression: In vitro Model

Morristown, N.J. – OmniActive Health Technologies is presenting a poster on the study Soluble Lutein Inhibits Cholinesterase and Reduces Ultraviolet Radiation-Induced Inflammation and Immunosuppression: In vitro Model at The Macular Carotenoids Conference’s (MCC) annual meeting, taking place from July 8th – 10th at Downing College, Cambridge University (UK). The study was conducted by Vijaya Juturu Ph.D., F.A.C.N., Manager of Global Scientific and Clinical Affairs, Khadija Ghanam, Ph.D. Clinical Nutritional Biochemist, and Jayant Deshpande, Ph.D., CTO—all of OmniActive Health Technologies.

This in vitro study evaluated the effect of the macular carotenoids— lutein and the two zeaxanthin isomers (Lutemax 2020®)— on cholinesterase activity and antioxidant enzymes in response to ultraviolet (UV) irradiation. Lutein and zeaxanthin isomers may ameliorate the effects of mild UV irradiation on Retinal Pigment Epitheleal (RPE) cells, as shown by expression of genes involved in cell proliferation, inflammation, immune function and wound healing. Lutein and zeaxanthin isomers inhibited cholinesterase activity and enhanced catalase activity in cells exposed to mild irradiation. These results suggest inhibition of cholinesterase enzyme and enhancing antioxidant enzymes may have several therapeutic applications such as neurodegenerative disorders and myasthenia gravis.

“We are excited to see from this Lutemax® 2020 study these new insights into the critical role that lutein and zeaxanthin isomers (RR-zeaxanthin and RS (meso)-zeaxanthin) may play in eye health, specifically as potent antioxidants and antiinflammatory agents protecting retinal tissue,” stated Jayant Desphande, Chief Technology Officer, OmniActive Health Technologies.

OmniActive— leaders in scientifically-validated, premium ingredients—offers the most comprehensive line of macular carotenoids. The study Soluble Lutein Inhibits Cholinesterase and Reduces Ultraviolet Radiation-Induced Inflammation and Immunosuppression: In vitro Model is a product of the OmniActive’s robust scientific program as well as another significant addition to the growing science on the macular carotenoids.

For more information on OmniActive or the company’s award-winning ingredients, technologies or research visit omniactives.com or contact l.doyle@omniactives.com.

About the Macular Carotenoids Conference
This three day conference brings together the premier researchers to explore up-to-date and evidence-based hypotheses, as well as to further support research data into the role of the macular carotenoids in age-related macular degeneration (AMD), vision, and cognitive function. MCC was founded by The Howard Foundation—a world-recognized charitable trust established in 1982—which provides funding for biomedical research in key areas of health including nutrition. Highlights of The Howard Foundation include research into the means of relieving malnutrition, especially in undeveloped countries.

About OmniActive Health Technologies
OmniActive Health Technologies (www.omniactives.com) offers a range of quality ingredients, which are innovative and scientifically validated for dietary supplementation, nutritional fortification, functional food/beverage, coloring, flavor enhancement and personal care applications. The company addresses complex challenges for customers in the dietary supplement, food and beverage space using technology-driven, sustainable solution with application support within a global regulatory framework. Whether looking for a new ingredient to add to a finished product, or an ingredient solution to enhance an existing ingredient, you will find unmatched innovation at OmniActive.

Core products include carotenoids, plant extracts and specialty functional ingredients. OmniActive leverages international R&D strengths to deploy an array of state of the art manufacturing technologies in extraction, purification, isolation and delivery of nutritional actives. The company’s manufacturing operations are located at multiple sites in India and are cGMP and HACCP system compliant.

KitoZyme Clinical study completed Promising results

Herstal, Belgium – A new clinical study, the full results of which are soon to be published in a renowned scientific journal, has just demonstrated the excellent results achieved with one of the company’s flagship products, KiOnutrime-CsG®, which helps combat excess weight and obesity.

Objective, results and impact of the clinical study

KitoZyme operates in three segments of the healthcare sector: digestive health, weight management and cardiovascular health. The study that has just been completed related to a product in the weight-management segment. More specifically, the objective was to verify and demonstrate the reduction in bodyweight in overweight and obese subjects due to the lipid absorbing capacity of the innovative product developed by KitoZyme, derived from a natural fibre of fungal origin.

The conclusion and results of this clinical study are very promising since patients recorded a clear, progressive reduction in their weight. Around one hundred patients were involved in the study, which also demonstrated statistically significant reductions in body fats and abdominal, hip and waist measurements in people who took KiOnutrime-CsG®.

‘In addition to confirming the company’s expertise, from the time they are published these excellent clinical study results should allow KitoZyme to proceed with its expansion, in particular in India and the Middle East, by offering a safe solution for overweight or obese people,’ stated Mr François Blondel, KitoZyme’s CEO. ‘Having already enjoyed a year of strong growth last year, we should achieve double-figure sales growth again this year’, he added.

The clinical trial requirements in detail
The multicentre clinical trial took place in four hospitals and medical research centres between the end of 2014 and the start of 2015. A total of 96 people, men and women who were overweight (BMI of 26 to 35) and aged between 18 and 65 years, were divided into two groups.  The 64 people in the treatment group were given five capsules per day, each containing 500 mg of KiOnutrime-CsG® .The 32 people enrolled in the control group followed the same procedure but their capsules contained a placebo. All of the patients maintained their usual eating habits and did not change their lifestyle. Weight loss was on average 3.2 kg in the group receiving treatment.

The unique nature of KitoZyme’s chitosan
KiOnutrime-CsG® is a unique natural fibre extracted from fungi using a patented process developed by KitoZyme. It dissolves in 10 minutes in the acidic environment of the stomach. That means that a dose can be administered almost immediately before a meal and makes it convenient and easy for consumers to take. It is also suitable for vegetarians and is certified halal and kosher.

KiOnutrime-CsG® is authorised in the European Union under the Novel Foods Regulation and is also approved by the European Food Safety Authority (EFSA) to bear the health claim that it maintains a healthy level of cholesterol (lipid) in the blood.

This active ingredient also holds GRAS (Generally Recognised As Safe) status as awarded by the United States Food and Drug Administration (FDA). Obesity worldwide The World Health Organisation (WHO) stated in 2014 that more than 1.9 billion adults over the age of 18 were overweight and 600 million of those were obese. The level of obesity worldwide continues to rise each year, both in industrialised and developing countries.

Obesity is associated with a significant rise in the risks of chronic diseases such as cardiovascular
disorders, diabetes and some cancers.

For more information, visit the website www.kitozyme.com

About KitoZyme
KitoZyme is active in the bio-chemistry and health sector. The company, based in Liège, is today the world leader in the production of vegetal chitosan. Based on its patented bio-polymers, KitoZyme designs, manufactures and markets medical devices, food supplements and ingredients which are today distributed in over 20 countries worldwide. The unique properties of chitosan have enabled products to be developed in the fields of weight management, digestive and cardiovascular health, as well as a series of specific applications.